Tumour ECs are able to selectively upregulate inhibitory receptors of T cell activation including programmed cell death protein ligand 1 (PD-L1), programmed cell death protein ligand 2 (PD-L2), T-cell immunoglobulin mucin-3 (TIM3), and B7-H3 (also known as CD276) [25,26,27]. Here, CD276 is linked to neoplasm.